{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-018398","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.486084+00:00","generated_at":"2026-05-18T08:58:38.874992+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MAIA doses first patient in Phase 2 expansion for ateganosine in advanced NSCLC; median OS 17.8 months","bullets":["First patient dosed in Taiwan in THIO-101 expansion for 3L NSCLC after CPI/chemo failure.","Median overall survival of 17.8 months observed in 22 patients (95% CI lower bound 12.5 months) in third-line setting.","Expansion includes two arms: ateganosine+cemiplimab (Libtayo) and monotherapy; screening in Europe/Asia.","Regeneron supplies Libtayo for combination cohort."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-018398","json":"https://secwatch.observer/filing/0001641172-25-018398.json","markdown":"https://secwatch.observer/filing/0001641172-25-018398.md","text":"https://secwatch.observer/filing/0001641172-25-018398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225018398/0001641172-25-018398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225018398/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:58:38.874992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}